Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted pill shows promise for japanese blood cancer patients

NCT ID NCT04172246

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called zanubrutinib in 55 Japanese patients with B-cell blood cancers that had come back or not responded to prior treatment. The goal was to check safety and how well the drug works. Zanubrutinib is taken as a pill twice daily and targets a protein that helps cancer cells grow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zanubrutinib (a targeted cancer drug taken as a pill)
What this could lead to
If successful, zanubrutinib could offer a new treatment option for Japanese patients with certain B-cell blood cancers.
What could go wrong
This is an early-phase study with a small number of participants (55). Results may not apply to all patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia follicular lymphoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma neoplasm of mature B-cells Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MATURE B-CELL MALIGNANCIES

Contacts and locations

Locations

  • Aiiku Hospital

    Sapporo, Hokkaido, 064-0804, Japan

  • Aomori Prefectural Central Hospital

    Aomori, 030-8553, Japan

  • Chiba Cancer Center

    Chiba, Chiba, 260-8717, Japan

  • Gifu Municipal Hospital

    Gifu, 500-8513, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, 241-8515, Japan

  • Kobe City Medical Center General Hospital

    KobeShi, Hyōgo, 650-0047, Japan

  • Kurume University Hospital

    KurumeShi, Fukuoka, 830-0011, Japan

  • Matsuyama Red Cross Hospital

    Matsuyama, Ehime, 790 8524, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital

    ChuoKu, Tokyo, 104-0045, Japan

  • National Hospital Organization Hokkaido Cancer Center

    Sapporo, Hokkaido, 003-0804, Japan

  • National Hospital Organization Okayama Medical Center

    Okayama, 701-1192, Japan

  • The Japanese Red Cross Nagasaki Genbaku Hospital

    Nagasaki, 852-8511, Japan

  • Toyohashi Municipal Hospital

    Toyohashishi, Aichi-ken, 441-8570, Japan

  • Yokohama Municipal Citizens Hospital

    Yokohama, 221-0855, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.